Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a NRF2 mutation
https://finance.yahoo.com/news/calithera-receives-fda-fast-track-110000872.html
Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a NRF2 mutation
https://finance.yahoo.com/news/calithera-receives-fda-fast-track-110000872.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.